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Microvesicles from brain-extract—
treated mesenchymal stem cells 
improve neurological functions in a 
rat model of ischemic stroke
Ji Yong Lee1,*, Eiru Kim2,*, Seong-Mi Choi1, Dong-Wook Kim3, Kwang Pyo Kim4, Insuk Lee2 & 
Han-Soo Kim1,5
Transplantation of mesenchymal stem cells (MSCs) was reported to improve functional outcomes in a 
rat model of ischemic stroke, and subsequent studies suggest that MSC-derived microvesicles (MVs) can 
replace the beneficial effects of MSCs. Here, we evaluated three different MSC-derived MVs, including 
MVs from untreated MSCs (MSC-MVs), MVs from MSCs treated with normal rat brain extract (NBE-MSC-MVs), 
and MVs from MSCs treated with stroke-injured rat brain extract (SBE-MSC-MVs), and tested their 
effects on ischemic brain injury induced by permanent middle cerebral artery occlusion (pMCAO) in rats. 
NBE-MSC-MVs and SBE-MSC-MVs had significantly greater efficacy than MSC-MVs for ameliorating 
ischemic brain injury with improved functional recovery. We found similar profiles of key signalling 
proteins in NBE-MSC-MVs and SBE-MSC-MVs, which account for their similar therapeutic efficacies. 
Immunohistochemical analyses suggest that brain-extract—treated MSC-MVs reduce inflammation, 
enhance angiogenesis, and increase endogenous neurogenesis in the rat brain. We performed mass 
spectrometry proteomic analyses and found that the total proteomes of brain-extract—treated MSC-
MVs are highly enriched for known vesicular proteins. Notably, MSC-MV proteins upregulated by brain 
extracts tend to be modular for tissue repair pathways. We suggest that MSC-MV proteins stimulated 
by the brain microenvironment are paracrine effectors that enhance MSC therapy for stroke injury.
Cell transplantation may become a therapeutic option for patients with central nervous system (CNS) diseases. 
There is increasing evidence that mesenchymal stem cells (MSCs) ameliorate functional deficits in a variety of CNS 
disease models, such as cerebral ischemia, spinal cord injury, Parkinson’s disease, and demyelinating diseases1–3. 
We and other groups have shown that in animal models, MSCs can improve functional deficits induced by 
ischemic stroke4–6. Therapeutic benefits are evident within days of cellular injection. By contrast, the rare event of 
cellular transdifferentiation of MSCs into neural cells, followed by integration into complex neural connections, 
may take weeks or months6,7. These results suggest that paracrine factors from MSCs could provide a promising 
treatment strategy for various CNS diseases.
Recent studies on MSCs have shown that the secretome, exosome, and microvesicle (MV) fractions of condi-
tioned media mimic the beneficial effects of MSCs8,9. We reported an MV proteome derived from human bone 
marrow MSCs that may be highly relevant for tissue regeneration10. Although the nature of the essential compo-
nents responsible for the therapeutic effects of MSCs remains to be determined, MVs and exosomes derived from 
MSCs are potential candidates. In various experimental disease models, such as acute kidney injury11, myocardial 
infarction12, liver cirrhosis13, endotoxin-induced lung injury14, and ischemic stroke15, MVs and exosomes have 
exhibited regenerative capacities comparable to those exerted by MSCs.
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MVs are submicron-sized membranous vesicles that are either actively released from cells via secretory com-
partments or shed from cell surface membranes. MVs are generated by many cell types and serve as vehicles that 
transfer biological information (e.g., protein, mRNA, and miRNA) to distant cells, thereby affecting their gene 
expression, proliferation, differentiation, and function16. An increase in MSC-derived MVs can be observed in 
the blood of stroke patients17. The transcript and protein profiles of MSCs change in response to the microenvi-
ronment18. Thus, we hypothesised that culturing MSCs with brain extract in vitro would elicit cell responses and 
changes in the composition of their secretomes, including changes in soluble factors and MVs known to regulate 
cell proliferation, differentiation, inflammation, tissue regeneration, and angiogenesis.
In this study, we investigated whether MSC-MVs and MVs isolated from MSCs treated with normal 
(NBE-MSC-MVs) and stroke (SBE-MSC-MVs) rat brain extract would improve functional recovery and tissue 
regeneration after the administration into a rat model of stroke induced by permanent middle cerebral artery 
occlusion (pMCAO).
Results
MVs from MSCs treated with normal and stroke-injured brain extracts ameliorate functional 
deficits in rat pMCAO with similar efficacy. In response to tissue injury, tissue repair and regeneration 
signals may be delivered to and sensed by resident stem cells. These stem cells then generate MVs, which are par-
acrine mediators that can reprogram the fate of other local stem cells19. Systemic or local administration of MSCs 
provides functional benefits in a number of animal stroke models. We hypothesised that MVs from MSCs signifi-
cantly contribute to the observed benefits of MSC administration, and signalling molecules secreted from a dam-
aged microenvironment could enhance the therapeutic effect of MSC-MVs. To test these hypotheses, we analysed 
the therapeutic effect of NBE-MSC-MVs, SBE-MSC-MVs, and untreated MSC-MVs. To examine the therapeutic 
effects of these three MV preparations, we induced a pMCAO model of the ischemic brain in rats. A single injec-
tion of MVs (0.2 mg/kg rat body weight) of NBE-MSC-MVs, SBE-MSC-MVs, and MSC-MVs was administered 
48 h after the induction of pMCAO via the right common carotid artery. After induction of ischemic stroke, body 
weight change was observed in all the rats. Loss of body weight was significantly attenuated in groups treated 
with NBE-MSC-MVs or SBE-MSC-MVs compared with that of a control group treated with phosphate buffered 
saline (PBS) on days 3 and 7, but was not significantly different than that of rats treated with MSC-MVs (Fig. 1A).
Behavioural performance after ischemic stroke was assessed using the following tests: open field, foot fault, 
beam balance, prehensile traction, and torso-twisting. All rats exhibited severe functional deficits at postoperative 
day 1, whereas sham controls showed no evidence of functional deficits. However, starting at 3 days after treat-
ment, rat groups treated with NBE-MSC-MVs or SBE-MSC-MVs exhibited significant functional enhancement 
for all parameters (Fig. 1B–F) compared with that of the PBS-treated control group. We observed that untreated 
MSC-MVs provided no significant improvement in the torso-twisting and line cross tests (Fig. 1B,C), and less 
significant improvement than that of NBE-MSC-MVs in the beam balance test and the modified neurological 
severity score (mNSS) (Fig. 1D,F). Notably, the administration of SBE-MSC-MVs did not show better behav-
ioural outcome compared with that of NBE-MSC-MVs in all parameters. Conversely, the analyses revealed that 
rats treated with NBE-MSC-MVs tended to achieve slightly better scores in the beam balance test and mNSS. 
These combined results suggest that the brain extract microenvironment facilitates the therapeutic activity of 
MSC-MVs, and brain extract derived from a pathological (stroke) brain does not provide additional benefits in 
promoting the therapeutic effect of MSC-MVs and improving neurological outcome.
MVs from MSCs treated with normal and stroke-injured brain extracts reduce brain infarc-
tion area with similar efficacy. Brain infarction area (the ratio of the damaged ipsilateral area to the 
contralateral hemisphere area) was measured via 2,3,5,-Triphenyl tetrazolium chloride (TTC) staining of the 
brain on post-treatment day 7. Infarct lesions primarily appeared in the cortex and striatum. The infarction area 
was demonstrably larger in ischemic brains treated with PBS than in those treated with NBE-MSC-MVs and 
SBE-MSC-MVs (Fig. 2). The infarction area of PBS-treated (control) rats was 59.19 ± 3.95%. By contrast, the 
infarction area was significantly reduced in rats treated with NBE-MSC-MVs (42.31 ± 2.80%) or SBE-MSC-MVs 
(43.00 ± 2.98%) (P < 0.01). A rat group treated with MSC-MVs showed a tendency of reduction in infarction 
area (45.70 ± 7.95%), but this reduction was not statistically significant for the given sample size. There was no 
significant difference in lesion volume between groups treated with NBE-MSC-MVs or SBE-MSC-MVs, indicat-
ing that there is no significant difference between normal and stroke-injured brain extracts for MV stimulation. 
These combined results suggest that both normal and injured brain extracts can enhance the therapeutic effects 
of MSC-MVs by reducing infarction area, and extract from injured brains does not confer greater efficacy than 
extract from normal brains in promoting the therapeutic effect of MSC-MVs.
Extracts of normal and stroke-injured brains have similar profiles of key signalling molecules. 
MSCs are known to respond to microenvironmental changes and, conversely, function to maintain microenvi-
ronmental homeostasis. Therefore, it is reasonable to hypothesise that signalling molecules secreted in response 
to local tissue damage can further promote the therapeutic effect of MSCs. However, we observed no signifi-
cant enhancement of therapeutic effect by MSCs preconditioned with stroke-injured brain extract compared 
with that of MSCs preconditioned with normal brain extract. We investigated whether the functional effects 
induced by treatment with brain extracts were due to molecules in the extracts that facilitated the secretion and/
or enhanced the therapeutic effects of MSC-MVs. This experiment was performed by analysing the expres-
sion levels of 90 key signalling proteins (such as cytokines) in each brain extract using a rat cytokine array (see 
Materials and Methods). Consistent with the observed similarity in the therapeutic efficacy conferred by normal 
and stroke-injured brain extracts, the measured quantities of 90 key signalling proteins showed high positive 
linear correlation (r2 = 0.88) in the two extracts, which suggested that they contained similar signalling-protein 
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profiles. This can explain why extract of the stroke-injured brain does not confer additional enhancement of the 
therapeutic benefit conferred by extract of the normal brain.
MVs from MSCs treated with brain extract induce neurogenesis and modulate inflammation 
in ischemic tissue. Previous studies show that ischemic stroke promotes spontaneous neurogenesis in the 
subventricular zone (SVZ) and subgranular zone of the hippocampus and induces migration of neuroblasts to 
the ischemic boundary20,21. To examine the effect of MSC-MVs treated with brain extract on the proliferation 
of neural progenitor cells and immature neurons in the ischemic region, sagittal sections of brain tissue were 
stained for doublecortin (DCX), a marker of migrating neuroblast progenitor cells, 7 days after MV injection. 
The therapeutic efficacy and key signalling-protein profiles did not significantly differ between NBE-MSC-MVs 
and SBE-MSC-MVs (see Fig. 1). Therefore, we used NBE-MSC-MVs to perform immunohistochemical anal-
yses and investigate the underlying mechanisms of brain tissue regeneration. The number of DCX-positive 
migrating neuroblasts in the lateral ventricle area and hippocampal region of stroke-affected hemispheres sig-
nificantly increased after treatment with NBE-MSC-MVs compared to that of PBS (Fig. 3A), suggesting that 
Figure 1. Transplantation of NBE-MSC-MVs and SBE-MSC-MVs improves neurological outcomes.  
(A) Analysis of body weight changes after injection of MSC-MVs, NBE-MSC-MVs, or SBE-MSC-MVs. Loss 
of body weight was significantly attenuated in rat groups treated with NBE-MSC-MVs (P < 0.011, P < 0.02) or 
SBE-MSC-MVs (P < 0.025, P < 0.05) compared with a group treated with PBS at day 3 and 7, respectively.  
(B) Torso-twisting test (left and right side). Score change from PBS group for right side was significant for 
NBE-MSC-MVs (P < 0.04) at day 3, and for both NBE-MSC-MVs (P < 0.025) and SBE-MSC-MVs (P < 0.03) at 
day 7. (C) Open field test (line cross score). Score change from PBS group was significant for NBE-MSC-MVs 
(P < 0.025) and SBE-MSC-MVs (P < 0.03) at day 3. (D) Beam balance test. All injection groups (MSC-MVs, 
NBE-MSC-MVs, and SBE-MSC-MVs) showed significant improvement compared with the PBS group at day 3  
(P < 0.01, P < 0.001, P < 0.001, respectively) and day 7 (P < 0.012, P < 0.0001, P < 0.04, respectively). (E) Prehensile 
traction test. The score was significantly increased in animals treated with MSC-MVs (P < 0.0002) and NBE-
MSC-MVs (P < 0.05) compared with that of the PBS control group at day 3, and in NBE-MSC-MVs (P < 0.005) 
at day 7. (F) Modified neurological severity scores (mNSS) indicate that animals treated with NBE-MSC-MVs  
and SBE-MSC-MVs displayed significant functional enhancement at day 3 (P < 0.0001 and P < 0.002, 
respectively) compared with the PBS control group, but animals treated with MSC-MVs did not. At 7 days after 
injection, animals treated with MSC-MVs, NBE-MSC-MVs, and SBE-MSC-MVs showed significant functional 
enhancement compared with that of the PBS group (P < 0.002, P < 0.0001, and P < 0.01, respectively). *P < 0.05; 
**P < 0.01, ***P < 0.001; n = 10 per group; Day − 1, time of pMCAO surgery; Day 0, time of MV injection; Day 
3 and 7, 3 and 7 days after MV injection, respectively. Sample sizes are n = 5 for sham-operated, n = 10 for NBE-
MSC-MV and SBE-MSC-MV treatment groups, and n = 7 for MSC-MV treatment group.
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NBE-MSC-MVs potentially promote neurogenesis by neural stem cells in the hippocampus and SVZ, and these 
cells migrate toward the ischemic boundary after stroke. By contrast, only a few DCX-positive cells confined to 
the SVZ were detected contralateral to the ischemic lesion in untreated rats (data not shown).
We also investigated the effect of NBE-MSC-MVs on angiogenesis in the ischemic region 7 days after MV 
injection using α -smooth muscle actin (α -SMA) as a prominent marker of vascular smooth muscle cells (Fig. 3B). 
The α -SMA-positive cells were identified in the ipsilateral hippocampal area. The number of α -SMA-positive cells 
significantly increased in the NBE-MSC-MV-treated group (8.5 ± 1.94) compared with the PBS-treated control 
group (3.25 ± 0.49). These results suggest that administration of NBE-MSC-MV promotes neovascularisation 
in the ischemic area after a stroke. We demonstrated previously that pMCAO in the rat and subsequent MSC 
transplantation reduced glial fibrillary acidic protein (GFAP)6, which is a marker of astrogliosis. A similar immu-
nosuppressive effect was observed in the pMCAO rats treated with NBE-MSC-MVs (Fig. 3C). Immunostaining 
revealed that the number of GFAP-positive astrocytes was significantly reduced in the ischemic striatal region of 
NBE-MSC-MV-treated rats compared with that of the control group. These results indicate that NBE-MSC-MV 
treatment can reduce astrocyte activation, suggesting anti-inflammatory and anti-astrogliosis effects during 
ischemic stroke.
Increased expression of pro-inflammatory cytokines is considered as a hallmark of inflammation after stroke 
in the ischemic hemisphere22. We found that TNF-α and progranulin (PGRN) levels increased in the lesions 
of PBS-treated control rats (Fig. 4A,B). Tumour necrosis factor-stimulated gene (TSG)-6, which is induced by 
inflammatory cytokines such as TNF-α and IL-1 as a part of the compensatory mechanism of tissue repair23, is 
slightly upregulated in the lesions of PBS-treated groups. Treatment with NBE-MSC-MVs greatly upregulated 
expression of the anti-inflammatory cytokines IL-10 (1.9-fold increase) and TSG-6 (3.2-fold increase) in the rat 
stroke model. Conversely, expression of the pro-inflammatory factors tumour necrosis factor (TNF) and pro-
granulin (PGRN) was significantly attenuated in brain tissue treated with NBE-MSC-MV compared with that of 
PBS-treated brain tissue.
Figure 2. NBE-MSC-MV and SBE-MSC-MV injection reduces infarct size in a rat stroke model.  
(A) Schematic diagram depicting the experimental design of this study. Numerals in the black bar represent 
the days of experiment. Day − 1, time of pMCAO surgery; Day 0, time of MV injection; Day 3 and 7, 3 and 7 
days after MV injection. Downward arrows indicate the days for behavioural tests and weight measurement. 
Upward arrows indicate the days for treatments and brain tissue sampling. (B) Representative TTC-stained 
brain sections from rats treated with PBS (control), MSC-MVs, NBE-MSC-MVs, and SBE-MSC-MVs show 
ischemic lesions on day 7 after MV treatment. (C) Bar graph depicting infarct size in all animals. The infarct 
area in the ipsilateral hemisphere is expressed as a percentage of the contralateral hemisphere area. Values are 
indicated as means ± SEM. **P < 0.01 compared with controls. Sample size n = 5 for sham control, n = 10 for 
NBE-MSC-MV and SBE-MSC-MV treatment groups, and n = 7 for MSC-MV treatment group.
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Figure 3. NBE-MSC-MV administration increases neurogenesis and reduces reactive astrogliosis at the 
ischemic boundary in the rat brain. (A) Compared with PBS control treatment, the number of DCX-positive 
cells at the ischemic boundary significantly increased immediately after NBE-MSC-MV treatment. *P < 0.05, 
**P < 0.01, ***P < 0.001, n = 5 per group. (B) Representative micrographs of α -SMA-positive vessels in 
ipsilateral hippocampal vessels at day 7. Compared with PBS control treatment, the number of α -SMA-positive 
vessels increased in the ipsilateral hippocampal area after NBE-MSC-MV treatment. Data are presented as 
mean numbers of α -SMA-positive vessels per group. *P < 0.05, n = 5 per group. (C) The number of GFAP-
positive cells significantly decreased in response to NBE-MSC-MV transplantation compared with that of PBS 
control injection at day 7. Data are presented as percent of GFAP-positive area/field. *P < 0.05, n = 5 per group. 
Scale bar = 200 μ m. Values are indicated as means ± SD.
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The proteomes of MSC-MVs treated with brain extract are highly enriched for known vesicular 
proteins. To identify the therapeutic factors associated with the observed behavioural recovery, neurogenesis, 
and immunosuppression conferred by MSC-MVs treated with brain extract, we analysed the NBE-MSC-MV 
and SBE-MSC-MV proteomes using mass spectrometry. Peptide spectra derived from mass spectrometry-based 
proteomic analysis were searched against the Human Ensembl GRCh37.7524 protein database. Several database 
search algorithms have complementary sensitivity and specificity. MSblender25 software increases the number of 
peptides identified by statistically combining search scores from multiple algorithms. We integrated the database 
search scores from three algorithms (Comet-2014.01_rev.026, MSGFDB-v778027, and Myrimatch-2.1.13828) in 
our proteome pipeline. An identical analysis was performed for spectral data from three batches of MSC-MV 
samples treated with brain extract and for previously published spectral data of control untreated MSC-MVs29.
Statistical integration of the search results enabled the identification of 1,523 human proteins from 775 genes 
that appeared in at least one batch, 921 proteins from 474 genes that appeared in at least two batches, and 591 
proteins from 320 genes that appeared in all three batches of NBE-MSC-MVs. Similar analysis identified 1,349 
human proteins from 669 genes that appeared in at least one batch, 807 proteins from 465 genes that appeared 
in at least two batches, and 521 proteins from 317 genes that appeared in all three batches of SBE-MSC-MVs 
(Supplementary Table S1). We found 1,183 proteins (70% of the union proteome set) that were present in both 
proteomes. Consistent with our previous report, we detected signatures of the endosome and a typical set of 
proteins associated with the exosome/MV, such as glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 14-3-3 
proteins, Gα proteins, clathrin, annexins (ANXs), Rab proteins, actin, tubulin, HSP70, and HSP90. The pro-
teome also included proteins associated with MV/exosome biogenesis, vesicle trafficking, Rab-related GTPases, 
anti-apoptosis/programmed cell death, and neuron differentiation/neurogenesis. We searched the NBE-MSC-MV 
and SBE-MSC-MV proteomes using Vesiclepedia30, a database of vesicular proteins created from curation of the 
literature (Fig. 5A and Supplementary Fig. S1A). Both NBE-MSC-MV and SBE-MSC-MV proteomes contained 
proteins that were identified in at least one batch and were highly enriched for MV, exosome, and microparticle 
proteins annotated in the Vesiclepedia database, suggesting that our proteomic study reliably identified the MV 
proteome. The same proteomes identified in at least two batches showed even higher enrichment for vesicular 
proteins in the Vesiclepedia database, indicating that a protein assigned to the proteome of brain-extract—treated 
MSC-MVs has a relatively strong probability of being a vesicular protein.
Upregulated proteins in NBE-MSC-MVs are functionally coherent. MSC-MVs treated with brain 
extract have enhanced therapeutic effects in a rat stroke model compared with that of untreated MSC-MVs. We 
hypothesised that upregulated proteins in these MVs had enhanced therapeutic effects. To test this hypothe-
sis, we identified MV proteins that were upregulated in response to brain extract. A total of 286 proteins from 
160 genes were upregulated in NBE-MSC-MVs compared with untreated MSC-MVs (Supplementary Table S2). 
We used the functional gene network HumanNet31, and a protein-protein interaction network derived from 
Human Protein Reference Database (HPRD)32, and found that the 160 upregulated genes were significantly more 
Figure 4. Anti-inflammatory effects of NBE-MSC-MVs in ischemic rat brain. (A) Representative RT-PCR 
results. (B) Quantification of inflammatory and anti-inflammatory gene expression. NBE-MSC-MVs reduced 
inflammatory factors and enhanced anti-inflammatory factors in ischemic rat brain tissue. Values are indicated 
as means ± SEM. *P < 0.05, **P < 0.01, n = 7 per group.
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connected to one another than would be expected by random chance (Fig. 5B). The high modularity of the upreg-
ulated NBE-MSC-MV proteins in co-functional or protein-protein interaction networks supports the idea that 
brain extract contains factors that activate MSC-MV proteins, which collaboratively participate in the process of 
tissue regeneration. We found similarly high network modularity of the upregulated SBE-MSC-MV proteins. A 
total of 286 proteins from 156 genes were upregulated in SBE-MSC-MVs compared with untreated MSC-MVs 
(Supplementary Table S3), and the unregulated genes identified in SBE-MSC-MV also were significantly more 
connected to one another than would be observed through random chance (Supplementary Fig. S1B).
Construction of a network of NBE-MSC-MV proteins involved in tissue repair. To gain a holistic 
view of therapeutic modules in NBE-MSC-MVs, we employed a systems biology approach. The 1,523 identified 
proteins (from 775 genes) in the human NBE-MSC-MV proteome represent a wide variety of functional catego-
ries. To reduce the complexity of functional analysis, we focused on four well-characterised functional categories 
involved in tissue repair: angiogenesis, neurogenesis, anti-inflammation, and apoptosis. We identified 272 genes 
associated with GO terms related to these four functional categories, with significant enrichment for each cate-
gory: 11 of 89 angiogenesis-related genes, 76 of 1,475 anti-inflammatory genes, 156 of 1,620 neurogenesis-related 
genes, and 122 of 1,697 apoptosis-related genes (P = 3.24 × 10−4, 4.46 × 10−4, 9.87  × 10−30, and 2.70  × 10−13, 
respectively, by Fisher’s exact test) were represented (Supplementary Table S4). We then constructed a network of 
the 272 therapeutic genes by projecting them on the HumanNet functional network (Fig. 6). HumanNet con-
nected 247 of the 272 genes with 1,439 links. This densely wired network suggests a high degree of functional 
association among NBE-MSC-MV proteins belonging to these four functional categories. Notably, the network 
was highly enriched for upregulated NBE-MSC-MV proteins (P = 1.91 × 10−80, Fisher’s exact test), suggesting 
that stimulating factors from brain extract may target these MSC-MV proteins. We were able to construct a sim-
ilar protein network for SBE-MSC-MV (Supplementary Fig. S2), which has 1,294 links among 222 genes belong-
ing to the four functional categories involved in tissue repair (Supplementary Table S5). These results also 
demonstrated the importance of proteomic analysis for investigating the effects of brain extract on the MSC-MV 
proteome in regulating tissue repair pathways.
Discussion
A number of clinical trials utilising MSCs from bone marrow, adipose tissue, and umbilical cord are underway, 
and evidence of the beneficial effects of cellular therapeutics for stroke and other neurodegenerative disorders is 
accumulating33–35. Previous studies reported that at least some of the therapeutic effects of transplanted cells were 
due to paracrine factors derived from the grafted cells; stem cells release membranous vesicles that can transmit 
information between cells, thereby reprogramming target cells36,37. These data prompted us to examine mem-
branous vesicles of the MSCs. In this study, we investigated the proteome and therapeutic effects of MVs derived 
from MSCs treated with brain extract in a rat model of ischemic stroke.
Our in vivo data demonstrated that both NBE-MSC-MVs and SBE-MSC-MVs improved neurological out-
comes and markedly reduced ischemic lesions. In agreement with previous findings38,39, the results of this study 
clearly support the hypothesis that MSC transplantation or injection promotes endogenous neurogenesis and 
improves behavioural deficits after ischemic stroke. The NBE-MSC-MVs significantly increased the level of 
Figure 5. Functional analysis of the NBE-MSC-MV proteome. (A) The proportions of vesicular proteins in 
the NBE-MSC-MV proteome supported by more than 1, 2, or 3 experimental batches and random proteomes 
(e.g., 10 random samplings of 1,000 proteins), indicating that the NBE-MSC-MV proteome is enriched for 
vesicular proteins annotated in the Vesiclepedia database. The degree of enrichment for vesicular proteins was 
higher for proteins identified in multiple NBE-MSC-MV batches. (B) Plots from ‘within-group connectivity’ 
and ‘sharing network neighbour’ analysis of the NBE-MSC-MV proteome for a functional network 
(HumanNet) and a protein-protein interaction network (HPRD). Box-and-whisker plots represent ‘within-
group edge count’ and ‘network neighbours overlap’ scores for 1,000 random gene sets of equal size, and red 
dots represent scores for the NBE-MSC-MV proteome.
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DCX, a reliable marker of neural progenitor cells/neuroblasts, in the lateral ventricles and hippocampal regions 
of stroke-damaged hemispheres, and there was a comparable increase in DCX-positive cells in the hippocampal 
region of the ischemic hemisphere in SBE-MSC-MV-treated rats (Supplementary Fig. S3). Although recent studies 
suggest that non-neurogenic cells with weak DCX-positivity are detectable in various brain regions40,41, we found 
that the number of strong DCX-positive cells was significantly elevated compared with that of PBS-treated con-
trols. Additionally, these DCX-positive cells were only detectable in the lateral ventricles and hippocampal regions 
of stroke-damaged hemispheres at day 7, but were not detected in the cerebral cortex or other brain regions.
We found that NBE-MSC-MVs significantly increased the number of α -SMA-positive cells in the ipsilateral 
hippocampus area after stroke. α -SMA is the actin isoform that predominates within vascular smooth muscle 
cells and has an important role in fibrogenesis42. Recent studies indicate that neovascularisation (angiogenesis and 
arteriogenesis) has considerable value for restorative stroke treatment. Previous studies have shown that stem cell 
transplantation promotes angiogenesis and arteriogenesis in the rat and mouse stroke models43,44. Sharma et al.45  
reported that the number of α -SMA-positive cells increased in the infarct region up to day 7, and thereafter incor-
porated into small vessels in a rat pMCAO-induced stroke model. In agreement with recent studies, our results 
suggest that MSC-MVs treated with brain extract have therapeutic effects on vascular remodelling (angiogenesis 
and arteriogenesis) after ischemic stroke.
NBE-MSC-MVs greatly attenuated astrocyte activation in the ischemic region. Astrocytes are known to have 
an important role in maintaining brain homeostasis; these cells become reactive in response to injury, stimulate 
cell proliferation, and release bioactive substances46, which are essential for controlling injury-mediated tissue 
damage and tissue remodelling. However, astrocyte dysfunction may contribute to disease mechanisms, resulting 
in global brain damage, such as ischemic stroke47. Over activation of reactive astrocytes, which involves inflam-
mation, leads to the formation of glial scars on regenerated brain tissue; this can be a significant barrier to tissue 
repair and regeneration. The reactive astrocytes around lesions in PBS-treated rats reflect a spontaneous repair 
mechanism that limits the spread of injury by forming glial scars48, and MSC or NBE-MSC-MV treatment can 
be beneficial by reducing the number of reactive astrocytes and thereby creating a microenvironment that is 
permissive for axonal sprouting and neurogenesis. Astrocytes are the most abundant cell type in the brain, and 
recent efforts have focused on the manipulation of astrocyte function in ischemic stroke49–51. The results of our 
study suggest that the mechanism underlying the therapeutic effects of NBE-MSC-MVs on ischemic stroke can 
encompass multiple actions that involve enhanced neurogenesis, cerebral blood supply, and anti-inflammation 
therapy in pMCAO rats.
Although the data show positive effects of MSC-MVs on the ischemic rat, no definitive conclusion can be 
reached due to the insufficient sample size for the significance test. MVs prepared from untreated MSCs have 
low protein yields (<0.3 mg/3 × 108 cells/48 h; data not shown), which could be a significant drawback for future 
clinical applications. We hypothesised that stimuli from the ischemic brain extract may increase the amount 
of MVs while preserving or enhancing the neuroprotective effects of MSCs. Indeed, the amount of MVs from 
MSC-conditioned medium was greatly increased by treatment with normal or ischemic brain extracts (2.2 mg /3 × 
108 cells/48 h for NBE-MSC-MVs and 2.5 mg/3 × 108 cells/48 h for SBE-MSC-MVs; data not shown).
Figure 6. Proposed network of 236 NBE-MSC-MV proteins belonging to four functional categories 
involved in tissue repair. Each node and edge of the network represents a human gene and a functional link, 
respectively. Functional links were derived from a co-functional network of human genes (HumanNet). We 
found that 236 of 272 genes associated with GO terms for angiogenesis, neurogenesis, anti-inflammation, and 
apoptosis are interconnected by functional links in the largest component of the network. The circumference 
of each node represents the proportion of proteins from each of the four functional categories: green for 
angiogenesis, blue for anti-inflammation, yellow for neurogenesis, and red for apoptosis. Upregulated NBE-
MSC-MV proteins are shown as purple nodes. The size of the purple node represents the fold change.
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Whereas our study analysed the proteomic profiles of MVs derived from MSCs treated with brain extract and 
the therapeutic value of MV proteins in a rat pMCAO model, we cannot exclude the possibility that mRNAs and 
miRNAs in the MV preparation played key roles in MSC-mediated neuroprotection. Recently, Xin et al. reported 
that exposure of MSCs to ischemic brain extract increased exosome levels of miRNAs associated with neurite out-
growth, suggesting that MSCs can produce high levels of therapeutic exosomes in response to injury37. In addition, 
they demonstrated that systemic administration of MSC-derived exosomes to rats with ischemic stroke improved 
functional outcomes, with therapeutic benefits reflecting those observed after systemically administering MSCs15.
We analysed the proteomic profiles of MVs from MSCs treated with normal and stroke-injured brain extract 
to identify the factors that contribute to improving neurological function after an ischemic stroke. We believe 
that the therapeutic effects of MVs on complex injuries such as ischemic stroke are likely to result from multiple 
factors rather than a single factor. Although these factors may include proteins, mRNA, miRNA, lipids, and 
other molecules, our primary focus was on identifying candidate MV proteins that participate in brain tissue 
regeneration. The extract-treated MSC-MV proteomes were characterised using MSblender52, an algorithm that 
integrates results from multiple peptide search algorithms via multivariate modelling and can identify substan-
tially more peptides and proteins than a single search algorithm, for a given confidence level. By comparing 
our results with a literature-based database, we determined that the majority of identified MV proteins were 
known vesicular proteins. These results indicate the reliability of our MSC-MV proteome sample preparation and 
mass spectrometry-based proteomic analysis. We also identified MSC-MV proteins upregulated by brain-extract 
treatment. Interestingly, enolase 2 (ENO2), which encodes a neuron-specific enolase (NSE) and was previously 
reported to be a marker of acute ischemic stroke53, was upregulated in extract-treated MSC-MVs.
We measured the functional coherence among the upregulated genes using their association in co-functional 
networks, and the resultant measures indicated significantly higher functional coherence than would be expected 
by random chance. This functional modularity suggests that signals from brain extract stimulate a group of func-
tionally coherent MV proteins, thereby activating therapeutic protein modules. The functional modularity also 
enabled reconstruction of the network of therapeutic effectors in MSC-MVs. We reconstructed a network of 
brain-extract—treated MSC-MV proteins involved in four well-characterised biological processes related to tis-
sue regeneration, anti-inflammation, angiogenesis, neurogenesis, and apoptosis, using the functional gene net-
work HumanNet. Notably, the network was highly enriched for MSC-MV proteins that were upregulated by 
brain-extract treatment. This is a strong indication that this network reflects brain extract-induced changes in the 
regulation of functional modules linked to MSC-MV therapeutic effects. Therefore, this network may contain key 
biopharmaceutical factors related to MSC-based cell therapy.
Previous studies proposed the beneficial effects of ischemic brain extracts over normal brain extracts18,54,55. 
Although we anticipated differences in the therapeutic efficacy of these two preparations under the assumption 
that stroke-injured brain extract contains stronger signals for tissue regeneration, our result showed similar effi-
cacy of MVs from MSCs treated with ischemic brain extract and normal brain extract in behavioural recovery 
and infarct size reduction. This could be due to the presence of cytotoxic or inhibitory factors in the ischemic 
brain extracts used for MSC preconditioning. Brain tissue affected by ischemic necrosis undergoes tissue destruc-
tion with massive inflammatory responses. Although progressive ischemic damage with marked increases 
in activated microglial cells and astrocytes in the infarct lesion was documented at 48 h after pMCAO in SD 
rats56, our cytokine array data revealed no statistically significant differences between normal brain extract and 
stroke-injured brain extract. This implies that stimulation of MSCs with normal brain extract and stroke-injured 
brain extract may generate MVs with comparable function and similar molecular contents. Indeed, we found that 
70% of identified proteins were shared between NBE-MSC-MV and SBE-MSC-MV proteomes.
Conclusions
Although a number of clinical trials of stem cell transplantation for neurodegenerative diseases such as stroke 
are underway, and an impressive body of evidence documenting the clinical benefits of such approaches is accu-
mulating, newly introduced approaches utilising MVs/exosomes derived from MSCs represent a novel and safe 
alternative. In this study, we demonstrated that MVs from brain-extract—treated MSCs exert therapeutic effects 
in a rat model of ischemia, promoting angiogenesis, neurogenesis, and anti-inflammation to enhance behavioural 
recovery and reduce infarct size. Therefore, our study supports the hypothesis that the therapeutic efficacy of 
MSCs is largely mediated by paracrine action of MVs. The use of MVs derived from preconditioned mesenchy-
mal stem cells offers a novel, safer alternative to cellular therapeutics for tissue regeneration.
Materials and Methods
Rat model of permanent middle cerebral artery occlusion and preparation of brain extract. All 
experimental procedures were performed in accordance with protocols approved by the Institutional Animal 
Care and Use Committee and the Institutional Review Board of Catholic Kwandong University-International 
St. Mary’s Hospital (Incheon, Korea). The investigators responsible for functional evaluation and molecular and 
histological studies were blinded to the treatment groups. All animals were housed in a temperature-controlled 
animal facility with a 12-h light/dark cycle. Male Sprague-Dawley rats weighing 200–250 g were anaesthetised 
with 3% isoflurane (Hana Pharm, Seoul, Korea) in a mixture of 80% N2O and 20% O2. Rectal temperature was 
maintained at 37 °C during the surgical procedure using heating pads. Permanent middle cerebral artery occlu-
sion (pMCAO) was induced as described previously6. Briefly, the left common carotid artery and external carotid 
artery were exposed through a 2 cm midline incision. Then, a 4-0 surgical nylon suture with a slightly enlarged 
round tip was inserted into the left internal carotid artery and advanced to the Circle of Willis. The thread was left 
in place until the rats were sacrificed.
To prepare ischemic brain tissue extracts, rats with similar neurological deficits were sacrificed 48 h after 
pMCAO18. To obtain the same quality of stroke-injured brain extract, we performed the experiments on rats with 
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clear hemiplegic symptoms and neurological deficits in behavioural tests at 48 h. A standard block centered at the 
territory of the MCAo (bregma − 1 ∼ + 1 mm) was obtained from the ipsilateral region by dissecting on ice from 
the ipsilateral region from stroke rat. Normal brain tissue extract were collected from the normal rat brain by 
same method. Subsequently, tissue pieces were homogenised by adding Dulbecco’s modified Eagle’s medium 
(DMEM; 150 mg/ml). Tissue homogenates were centrifuged twice for 60 min at 100,000 × g  at 4 °C, and then fil-
tered through a 0.2 μ m filter, after which protein content was quantified using the Bradford assay. The resulting 
cell- and MV-free brain extract supernatant was stored at − 80 °C.
Cytokine antibody array. An antibody-based cytokine array system (L Series 90, RayBio® Label-Based Rat 
Antibody Array 1, RayBiotech, Norcross, GA) was used to detect the levels of cytokines and growth factors in nor-
mal and stroke-injured brain extracts. Briefly, normal and stroke-injured brain extract samples were incubated 
with labelling reagent and washed according to the manufacturer’s instructions. Samples were diluted 1:50 (v/v) 
in blocking buffer and incubated on pre-blocked arrays overnight at 4 °C. Membranes were then incubated in 
streptavidin-conjugated peroxidase for 2 h, and exposed to a peroxidase substrate for 5 min before developing on X-ray 
film. Densitometric analysis was performed on a Kodak ImageStation 4000 M (Eastman Kodak Company, Rochester, 
NY) with background subtraction from spot edges. Spot data were normalised to a positive control spot on each array.
Microvesicle isolation from human mesenchymal stem cells. The human MSCs were obtained from 
adipose tissues of two patients (34- and 41-year old females) undergoing plastic surgery, after written informed 
consent, in accordance with the Institutional Review Boards (4-2010-0236) of Severance Hospital (Yonsei 
University Health System, Seoul), were supplied by Yonsei Cell Therapy Center (Yonsei University Health System) 
and cultured as described previously57. The in vitro and in vivo study was approved by the Institutional Review 
Board of Yonsei University (approval No. 2011-0087) and Catholic Kwandong University (CKU 01-2014-003). 
MVs derived from MSC were isolated from conditioned medium using ultracentrifugation as described previ-
ously, with minor modifications10. Briefly, the primary cultured MSCs (2 × 106 cells/flask) were seeded in 75 cm2 
culture flasks and cultured in DMEM containing 10% foetal bovine serum for 24 h. After extensive washing 
with PBS, culture medium was replaced with serum-free, low-glucose DMEM medium containing extract of 
normal brain tissues or ischemic brain tissues (15 mg/ml). The optimal time point for harvesting microvesi-
cles from cultured MSCs (either untreated or brain-extract—treated) was determined by cell viability based on 
flow cytometric analysis (Annexin V-PI staining) with the bicinchoninic acid (BCA) assay. We found apoptotic 
or necrotic bodies are the major contaminating components of microvesicles in conditioned media (data not 
shown). We therefore harvested microvesicles from cultured MSCs at 48 h for the highest protein contents with 
minimal apoptotic/necrotic cell death. Conditioned media of untreated MSCs or MSCs treated with normal or 
ischemic brain extracts were collected at 48 h, centrifuged once at 500 × g for 10 min, and then twice at 800 × g 
for 15 min. The supernatants were then concentrated by ultrafiltration using the Minimate TFF capsule system 
(PALL Corporation, Ann Arbor, MI) with a 100 kDa membrane. To enrich the MVs, the concentrated super-
natant was added onto 0.8 and 2.7 M sucrose cushions in 20 mM HEPES/150 mM NaCl buffer (pH 7.2), and 
subsequently ultracentrifuged twice at 100,000 × g for 60 min, which precipitates MVs derived from rat brain58,59. 
After centrifugation, the interface between the 0.8 and 2.7 M sucrose cushions was collected and diluted in PBS. 
For further purification of the MVs, sucrose cushion− enriched MVs were mixed with OptiPrep™ (final concen-
tration = 30%) and then pipetted into the bottom of a 12 ml tube. Next, 3 ml of 20% OptiPrep™ and 2.5 ml of 5% 
OptiPrep™ were prepared in 20 mM HEPES/150 mM NaCl buffer (pH 7.2) and layered sequentially, and the tubes 
were then ultracentrifuged at 200,000 × g for 3 h. The microvesicles were collected from the interface between 5% 
and 20% OptiPrep™ , diluted with 9 ml of PBS, and then ultracentrifuged at 100,000 × g for 1 h. The purified MVs 
were resuspended in PBS, and the protein concentration of each fraction was determined using refractometry and 
the Bradford dye assay. All fractions were stored at − 80 °C until use.
In vivo experimental protocol. For consistency in data analysis, we excluded rats showing neither 
hemiplegia nor neurological deficits at 24 h after the pMCAO procedure. Animals were randomised into four 
groups: PBS alone (n = 10), MSC-MVs (n = 7), NBE-MSC-MVs (MVs from MSCs treated with normal brain 
extracts, n = 10), and SBE-MSC-MVs (MVs from MSCs treated with stroke-injured brain extracts, n = 10). A 
sham-operated control group (n = 5) underwent the same procedure without vascular occlusion. A single injec-
tion of MSC-MVs, NBE-MSC-MVs, or SBE-MSC-MVs (0.2 mg/kg of rat body weight) was performed 48 h after 
pMCAO via the right common carotid artery.
Behavioural tests and modified neurological severity score (mNSS). For all animals, a battery of 
functional tests was performed 24 h before and 24 h after pMCAO and at 1, 3, and 7 days post-MV injection. 
Before the onset of ischemia, all rats were able to perform the tests and exhibited no abnormalities. All behav-
ioural tests were administered and scored by trained and experienced observers who were blind to the treatment 
groups of the animals. We assessed the motor weakness of rats subjected to pMCAO with a beam balance test, a 
torso-twisting test, a prehensile test, a foot fault test, and an open field test6. Change in body weight was calculated 
by subtracting baseline body weight (g) from the body weight measured post-pMCAO.
The modified torso-twisting test was adopted from a previous report60. Rats were examined for lateral move-
ments after elevation by their tails up to 10 cm above the surface of the testing area. The frequency of left or right 
swing was scored for 1 min. The score was 0 for torso twist, left and right swing; 1, asymmetrical twist < 30°; and 2, 
asymmetrical twist > 30°. Differential counts for torso-twisting were ipsilateral twist (same as infarct site) and 
contralateral twist (counter to infarct site). Baseline value of sham control was excluded in torso twisting, as rats 
without hemiplegic paralysis (as of sham control) display two extremes, either no side swing elevation (score 0) 
or swing elevation of complete symmetry (score 10~20).
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In the beam balance test, rats were placed at the centre of a beam (100 cm × 3 cm × 0.5 cm) and motor per-
formance was graded as a 6-point scale adapted from the previous description61. The score was 1, balances with 
steady posture and paws on top of the beam; 2, grasps side of beam and has shaky movement; 3, one or more paws 
slip off beam; 4, attempts to balance on the beam but falls off; 5, drapes over the beam but falls off; and 6, falls off 
the beam with no attempt to balance.
In the prehensile test, a steel bar (2 cm diameter and 100 cm long) placed horizontally 70 cm above a foam rub-
ber pad (7.5 cm thick) was used. After hanging the forepaws of the rat on the bar, the animal was released. Time 
to falling with rear limb movements was measured. The score 0 was assigned to rats that were able to hang for 5 s 
and bring rear limbs up, score 1 was assigned to rats hanging for 5 s with no rear limbs up, score 2 was assigned to 
rats hanging for 3–4 s, and score 3 was assigned to rats hanging for 0–2 s. The foot fault test measures the accuracy 
of forepaw placement on an equidistant grid (60 cm × 60 cm, 6 cm between grid lines) during 2 min. The open 
field test consisted of a wooden box (10 cm × 7.5 cm) with walls painted black and the floor painted white, which 
was divided into twelve squares (2.5 cm × 2.5 cm each). The animals were placed at the centre of the open field 
arena and tested in a quiet room. The number of lines crossed (at least two paws and nose in a quadrant), rotation 
(unidirectional circling), and rearing (animal standing upright on its hind legs) were recorded for 2 min.
The neurological severity score (NSS) was a composite of motor, sensory, and reflex test results as described 
previously62. The objective quantifications were based on the torso-twisting test, beam balance test, prehensile 
traction test, open field test (rotation frequency), and foot fault test. The mNSS score was 0, no deficits; 2, diffi-
culty in fully extending the contralateral forelimb (3 ≤ front foot fault < 10); 4, unable to extend the contralateral 
forelimb (front foot fault ≥ 10); 6, mild circling to the contralateral side (1 ≤ rotation or asymmetrical twisting 
< 5); 8, severe circling (rotation or asymmetrical twisting ≥ 5); and 10, falling to the contralateral side (prehensile 
traction ≤ 2).
Quantification and immunohistochemical assessment of infarct area. Seven days after MV trans-
plantation, rats were anaesthetised with Zoletil (Virbac S.A., France, 25 mg/kg) and perfused with phosphate 
buffered saline (PBS; pH 7.5). After performing the modified neurological severity score, rats were sacrificed with 
an overdose of chloral hydrate. Brains were immediately removed and weighed to obtain brain tissue wet weight. 
The brains were then sectioned into 2-mm-thick coronal slices with the aid of a brain matrix. Coronal brain slices 
were immediately immersed into 2% 2,3,5,-triphenyltetrazolium chloride (TTC) (Sigma, USA) for 20 min at 
37 °C, followed by fixation in a 4% paraformaldehyde solution overnight before analysis. The TTC-stained sec-
tions were photographed with a digital camera, and the infarct area of each section was determined with ImageJ 
software analysis. Indirect lesion area, in which the intact area of the ipsilateral hemisphere was subtracted from 
the area of the contralateral hemisphere, was calculated. Relative infarct area is presented as the percentage of the 
indirect lesion versus the contralateral hemisphere.
Each brain was fixed in 4% paraformaldehyde (PFA) for 24 h and washed in PBS. To create paraffin sec-
tions, tissues were dehydrated in a graded ethanol series and embedded in paraffin. Each paraffin-embedded 
brain was sectioned into 4 μ m thick layers with a microtome, deparaffinised in xylene for 10 min, and rehy-
drated in a graded alcohol series. Sections were boiled in 10 mM citric acid for 1 h, followed by the addition of 
a 5% bovine serum albumin (BSA) solution containing PBS and 0.5% Triton X-100. Then, brain sections were 
incubated with primary antibodies to doublecortin (DCX; Abcam, 1:100), glial fibrillary acidic protein (GFAP; 
Millipore, 1:100), and α -smooth muscle actin (α SMA; Abcam, 1:100) for 15–17 h at 4 °C. Sections were incubated 
overnight with primary antibodies, washed with PBS, and then incubated with fluorescence-tagged secondary 
antibodies (Alexa-Fluor® 488 or 594, 1:500, Molecular Probes, Eugene, OR, USA) for 1 h. A fluorescent micro-
scope (Olympus IX71) was used to examine the sections and capture fluorescent images. DCX-positive cells and 
α SMA positive cells in the hippocampus and the SVZ (cells/mm2) were quantified using the MetaMorph Imaging 
System (Molecular Device, Sunnyvale, CA). The GFAP positive area of the hippocampus image was measured and 
converted to the volume by multiplying the section thickness (4 μm).
RT-PCR analysis. Total RNA was extracted using TRIzol reagent. Standard reverse-transcription (RT) 
was performed using Maxim-RT Premix Kit (Invitrogen). RT-PCR was performed with PCR primers (Bioneer, 
Daejeon, Korea) under the conditions listed in Supplementary Table S6. The levels of β -actin were used as an 
internal control.
Nano-LC-ESI-MS/MS analysis. Briefly, tryptic peptides were applied to a home-made analytical column 
(75 μ m × 11 cm) packed with C18 regular 5 μ m sized resin. A linear 45 min gradient was achieved from 97% sol-
vent A (0.1% formic acid in H2O) to 60% solvent B (0.1% formic acid in acetonitrile) at a flow rate of 0.3 μ l/min. 
The separated peptide ions were then electrosprayed into the nano-electrospray ionisation (ESI) source. The elec-
trospray voltage was 1.9 kV, and 35% normalised collision energy was used for MS/MS. All MS/MS spectra were 
acquired by data-dependent scans in which the five most abundant spectra from the full MS scan were selected 
for fragmentation. The repeat count for dynamic exclusion was set to 1, the repeat duration was 30 s, the dynamic 
exclusion duration was set to 180 s, the exclusion mass width was 1.5 Da, and the list of dynamic exclusion was 50. 
Three independent samples of NBE-MSC-MVs were prepared and were subjected to mass spectrometry analysis.
Mass spectrometry-based proteome analysis. Tryptic peptides produced by in-gel digestion were 
analysed using a linear trap quadrupole (LTQ) mass spectrometer (Thermo Finnigan, San Jose, CA) coupled 
with an Eksigent Nano Ultra Performance Liquid Chromatography (uPLC) system (Eksigent Technologies, CA). 
Three independent samples of NBE-MSC-MVs were prepared and subjected to mass spectrometry. To iden-
tify peptides, we first used a free scaffold viewer (http://www.proteomesoftware.com/products/free-viewer/) 
and MSconverter-3.0.6585 to convert raw spectral data into MGF and mzXML format for use by peptide search 
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algorithms63. These MS/MS spectra were searched against the Human Ensembl GRCh37.7524 protein database 
using the MSblender25 algorithm, which statistically combines peptide identification scores obtained from multiple 
search algorithms using multivariate modelling. We ran three separate search algorithms, Comet-2014.01_rev. 026, 
MSGFDB-v778027, and Myrimatch-2.1.13828, against the spectral data. All algorithms were performed using the 
default parameter settings. Peptide scores from the three search algorithms were integrated with MSblender. We 
selected a set of proteins for functional proteome analysis by identifying peptides with > 1 spectral count in at 
least one batch, with false discovery rate (FDR) < 0.01.
Gene ontology (GO) analysis and construction of a therapeutic network. We obtained a human 
Gene Ontology (GO) annotation from NCBI. We manually filtered the identified proteins for annotated genes 
by GO terms related to angiogenesis, anti-inflammation, neurogenesis, and apoptosis, and generated a list of 
therapeutic genes. We then connected those genes by links with HumanNet31 to generate a therapeutic network 
composed of 236 therapeutic genes and 1,276 functional associations among them. Visualisation of the network 
was performed by Cytoscape-3.1.025.
Database analysis of vesicular proteins. To identify vesicular proteins in the proteome, we used 
Vesiclepedia30, a literature-based database of proteins from exosomes, MVs, and microparticles. We also meas-
ured coverage of the identified proteins among the 3,990 MV, microparticle, and exosome proteins of the database.
Identification of differentially expressed proteins and analysis of their functional coherence 
based on a human gene network. Differentially expressed proteins (DEPs) between brain-extract—
treated and control MSC-MVs were identified using qprot software64. Control, untreated MSC-MV proteome 
data were derived from our previous study29. We defined DEPs as those with an FDR threshold of 0.01. To test the 
functional coherence of our findings, we measured ‘within-group edge counts’ and ‘network neighbours overlap’ 
among upregulated proteins in the human functional gene network, HumanNet31, and a protein-protein interac-
tion network from the Human Protein Reference Database (HPRD)32.
Statistical analysis. Data are expressed as mean ±  standard error of mean (SEM) or mean ± standard devi-
ation (SD). Behavioural test and infarct area results were analysed by ANOVA and independent t-test using the 
Statistical Package for Social Sciences (SPSS) version 20. Differences with P < 0.05 were considered statistically 
significant.
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